Panels
Discover
Changing the status quo
Antibiotic susceptibility testing (AST) hasn’t seen true innovation in over 20+ years. All the while, bacteria have been evolving faster than science, creating resistance to lifesaving antibiotics.
According to the World Health Organization, antibiotic resistance is rising to dangerously high levels, becoming the next global health crisis. Selux is on a mission to combat superbugs and preserve the lifesaving power of antibiotics for future generations.
The global health crisis of antimicrobial resistant infections is a complex and multidimensional problem. One solution is the science and technology of Selux.
To preserve the lifesaving power of antibiotics we need faster diagnostic results, susceptibility testing on all sample types, testing against all commercially relevant antibiotics at one time, and a commitment to updated breakpoints.
Our Solution
Comprehensive menu
Selux is confronting this global health crisis head-on by redefining speed in rapid AST, with our proprietary Next Generation Phenotyping (NGP) System. The Selux rapid NGP System starts with our proprietary 384-well panel. Never before has an AST system been able to break free of panel real estate constraints, until now. This unique design was carefully created to help solve today’s health crisis of increasing antimicrobial resistance, while also preparing for the problems of the future.
Learn More
Fast results
the Selux NGP system offers speed, high throughput, accuracy, and updated breakpoints. The power inside the Selux Analyzer comes from utilizing our proprietary Viability Assay, and Surface Area Assay – each helping to create a more precise analysis of cell health than traditional AST has been able to do before. Through our Viability and Surface Area Assays, we’re able to detect a cell dying without waiting for cell death – providing fast, accurate, and comprehensive results.
Learn More
Updated breakpoints
Outdated breakpoints can put a patient’s life at risk and contribute to the global health crisis of antimicrobial resistance (AMR). The Selux NGP System offers broad dilutions that make updating breakpoints easy. We are committed to working towards future updates by working with the appropriate regulatory channels – at Selux we believe the burden of updated breakpoints should rest on us, not your lab.
Learn More
Redefining patient care and antibiotic stewardship with rapid AST
Despite the importance of antimicrobial susceptibility testing (AST) to infectious diseases patient care, current AST systems either limit result speed, accuracy, or consistency. This forces an overreliance on broad-spectrum antibiotics and contributes to antimicrobial resistance. While multiple rapid AST technologies are under development, these are restricted to bloodstream infections so they cannot address the vast majority of hospitalized patients with other infections. The Selux NGP System offers same shift results, direct from positive blood culture and isolates.
50%
Of antibiotics used in hospitals are either unnecessary or are prescribed incorrectly.
15
Every 15 minutes someone new dies of an antibiotic-resistant infection.
2050
The year by which superbugs are expected to surpass cancer as a leading cause of death.